[1] World Health Organization, WHO report on cancer: setting priorities, investing wisely and providing care for all (2020).
[2] The editorial board of the cancer statistics in japan, CANCER STATISTICS IN JAPAN-2019, Foundation for Promotion of Cancer Research (2020).
[3] A. Gilman, F.S. Philips, The Biological Actions and Therapeutic Applications of the B- Chloroethyl Amines and Sulfides, Science, 103, 409-36 (1946).
[4] Z.Y. Wang, Z. Chen, Acute promyelocytic leukemia: from highly fatal to highly curable, Blood, 111, 2505-15 (2008).
[5] B.J. Druker, S. Tamura, E. Buchdunger, S. Ohno, G.M. Segal, S. Fanning, J. Zimmermann, N.B. Lydon, Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells, Nat Med. 2, 561-6 (1996).
[6] D.J. Slamon, G.M. Clark, S.G. Wong, W.J. Levin, A. Ullrich, W.L. McGuire, Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science, 235, 177-82 (1987).
[7] J.G. Paez, P.A. Jänne, J.C. Lee, S. Tracy, H. Greulich, S. Gabriel, P. Herman, F.J. Kaye, N. Lindeman, T.J. Boggon, K. Naoki, H. Sasaki, Y. Fujii, M.J. Eck, W.R. Sellers, B.E. Johnson, M. Meyerson, EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science, 304, 1497-500 (2004).
[8] K. Sunami, H. Ichikawa, T. Kubo, M. Kato, Y. Fujiwara, A. Shimomura, T. Koyama, H. Kakishima, M Kitami, H. Matsushita, E. Furukawa, D. Narushima, M. Nagai, H. Taniguchi, N. Motoi, S. Sekine, A. Maeshima, T. Mori, R. Watanabe, M. Yoshida, A. Yoshida, H. Yoshida, K. Satomi, A. Sukeda, T. Hashimoto, T. Shimizu, S. Iwasa, K. Yonemori, K. Kato, C. Morizane, C. Ogawa, N. Tanabe, K. Sugano, N. Hiraoka, K. Tamura, T. Yoshida, Y. Fujiwara, A. Ochiai, N. Yamamoto, T. Kohno, Feasibility and utility of a panel testing for 114 cancer-associated genes in a clinical setting: A hospital-based study, Cancer Sci., 110, 1480-1490 (2019).
[9] J. Ferlay, M. Colombet, I. Soerjomataram, C. Mathers, D.M. Parkin, M. Pineros, A. Znaor, F. Bray, Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods, Int J Cancer, 144, 1941-1953 (2019).
[10] M.J. van de Vijver, Y.D. He, L.J. van't Veer, H. Dai, A.A. Hart, D.W. Voskuil, G.J. Schreiber, J.L. Peterse, C. Roberts, M.J. Marton, M. Parrish, D. Atsma, A. Witteveen, A. Glas, L. Delahaye, T. van der Velde, H. Bartelink, S. Rodenhuis, E.T. Rutgers, S.H. Friend, R. Bernards, A gene- expression signature as a predictor of survival in breast cancer, N Engl J Med, 347, 1999-2009 (2002).
[11] C.M. Perou, T. Sorlie, M.B. Eisen, M. van de Rijn, S.S. Jeffrey, C.A. Rees, J.R. Pollack, D.T. Ross, H. Johnsen, L.A. Akslen, O. Fluge, A. Pergamenschikov, C. Williams, S.X. Zhu, P.E. Lonning, A.L. Borresen-Dale, P.O. Brown, D. Botstein, Molecular portraits of human breast tumours, Nature, 406 747-752 (2000).
[12] T. Sorlie, C.M. Perou, R. Tibshirani, T. Aas, S. Geisler, H. Johnsen, T. Hastie, M.B. Eisen, M. van de Rijn, S.S. Jeffrey, T. Thorsen, H. Quist, J.C. Matese, P.O. Brown, D. Botstein, P.E. Lonning, A.L. Borresen-Dale, Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications, Proc Natl Acad Sci U S A, 98, 10869-10874 (2001).
[13] J.I. Herschkowitz, K. Simin, V.J. Weigman, I. Mikaelian, J. Usary, Z. Hu, K.E. Rasmussen, L.P. Jones, S. Assefnia, S. Chandrasekharan, M.G. Backlund, Y. Yin, A.I. Khramtsov, R. Bastein, J. Quackenbush, R.I. Glazer, P.H. Brown, J.E. Green, L. Kopelovich, P.A. Furth, J.P. Palazzo, O.I. Olopade, P.S. Bernard, G.A. Churchill, T. Van Dyke, C.M. Perou, Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors, Genome Biol, 8, R76 (2007).
[14] A. Prat, J.S. Parker, O. Karginova, C. Fan, C. Livasy, J.I. Herschkowitz, X. He, C.M. Perou, Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer, Breast Cancer Res, 12, R68 (2010).
[15] A. Romero, A. Prat, J.A. Garcia-Saenz, N. Del Prado, A. Pelayo, V. Furio, J.M. Roman, M. de la Hoya, E. Diaz-Rubio, C.M. Perou, T. Clades, M. Martin, Assignment of tumor subtype by genomic testing and pathologic-based approximations: implications on patient's management and therapy selection, Clin Transl Oncol, 16, 386-394 (2014).
[16] J.J. Gao, S.M. Swain, Luminal A Breast Cancer and Molecular Assays: A Review, Oncologist, 23, 556-565 (2018).
[17] F. Ades, D. Zardavas, I. Bozovic-Spasojevic, L. Pugliano, D. Fumagalli, E. de Azambuja, G. Viale, C. Sotiriou, M. Piccart, Luminal B breast cancer: molecular characterization, clinical management, and future perspectives, J Clin Oncol, 32, 2794-2803 (2014).
[18] P. Wirapati, C. Sotiriou, S. Kunkel, P. Farmer, S. Pradervand, B. Haibe-Kains, C. Desmedt, M. Ignatiadis, T. Sengstag, F. Schutz, D.R. Goldstein, M. Piccart, M. Delorenzi, Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures, Breast Cancer Res, 10, R65 (2008).
[19] A. Goldhirsch, E.P. Winer, A.S. Coates, R.D. Gelber, M. Piccart-Gebhart, B. Thurlimann, H.J. Senn, m. Panel, Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013, Ann Oncol, 24, 2206-2223 (2013).
[20] K. Dias, A. Dvorkin-Gheva, R.M. Hallett, Y. Wu, J. Hassell, G.R. Pond, M. Levine, T. Whelan, A.L. Bane, Claudin-Low Breast Cancer; Clinical & Pathological Characteristics, PLoS One, 12, e0168669 (2017).
[21] S. Badve, D.J. Dabbs, S.J. Schnitt, F.L. Baehner, T. Decker, V. Eusebi, S.B. Fox, S. Ichihara, J. Jacquemier, S.R. Lakhani, J. Palacios, E.A. Rakha, A.L. Richardson, F.C. Schmitt, P.H. Tan, G.M. Tse, B. Weigelt, I.O. Ellis, J.S. Reis-Filho, Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists, Mod Pathol, 24, 157-167 (2011).
[22] A. Prat, E. Pineda, B. Adamo, P. Galvan, A. Fernandez, L. Gaba, M. Diez, M. Viladot, A. Arance, M. Munoz, Clinical implications of the intrinsic molecular subtypes of breast cancer, Breast, 24 Suppl 2, S26-35 (2015).
[23] T. Reya, S.J. Morrison, M.F. Clarke, I.L. Weissman, Stem cells, cancer, and cancer stem cells, Nature, 414, 105-111 (2011).
[24] M.O. Idowu, M. Kmieciak, C. Dumur, R.S. Burton, M.M. Grimes, C.N. Powers, M.H. Manjili, CD44(+)/CD24(-/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome, Hum Pathol, 43, 364-373 (2012).
[25] J.E. Visvader, G.J. Lindeman, Cancer stem cells: current status and evolving complexities, Cell Stem Cell, 10, 717-728 (2012).
[26] A.K. Croker, A.L. Allan, Inhibition of aldehyde dehydrogenase (ALDH) activity reduces chemotherapy and radiation resistance of stem-like ALDHhiCD44(+) human breast cancer cells, Breast Cancer Res Treat, 133, 75-87 (2012).
[27] D.R. Rhodes, J. Yu, K. Shanker, N. Deshpande, R. Varambally, D. Ghosh, T. Barrette, A. Pandey, A.M. Chinnaiyan, ONCOMINE: a cancer microarray database and integrated data-mining platform, Neoplasia (New York, NY), 6, 1 (2004).
[28] J. Gao, B.A. Aksoy, U. Dogrusoz, G. Dresdner, B. Gross, S.O. Sumer, Y. Sun, A. Jacobsen, R. Sinha, E. Larsson, E. Cerami, C. Sander, N. Schultz, Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal, Sci Signal, 6, pl1 (2013).
[29] E. Cerami, J. Gao, U. Dogrusoz, B.E. Gross, S.O. Sumer, B.A. Aksoy, A. Jacobsen, C.J. Byrne, M.L. Heuer, E. Larsson, Y. Antipin, B. Reva, A.P. Goldberg, C. Sander, N. Schultz, The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data, Cancer Discov, 2, 401-404 (2012).
[30] M. Al-Hajj, M.S. Wicha, A. Benito-Hernandez, S.J. Morrison, M.F. Clarke, Prospective identification of tumorigenic breast cancer cells, Proc Natl Acad Sci U S A, 100, 3983-3988 (2003).
[31] C. Ginestier, M.H. Hur, E. Charafe-Jauffret, F. Monville, J. Dutcher, M. Brown, J. Jacquemier, P. Viens, C.G. Kleer, S. Liu, A. Schott, D. Hayes, D. Birnbaum, M.S. Wicha, G. Dontu, ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome, Cell Stem Cell, 1, 555-567 (2007).
[32] C. Hirschmann-Jax, A.E. Foster, G.G. Wulf, J.G. Nuchtern, T.W. Jax, U. Gobel, M.A. Goodell, M.K. Brenner, A distinct "side population" of cells with high drug efflux capacity in human tumor cells, Proc Natl Acad Sci U S A, 101, 14228-14233 (2004).
[33] P.E. Lonning, T. Sorlie, A.L. Borresen-Dale, Genomics in breast cancer-therapeutic implications, Nat Clin Pract Oncol, 2, 26-33 (2005).
[34] M. Balic, C. Thomssen, R. Wurstlein, M. Gnant, N. Harbeck, St. Gallen/Vienna 2019: A Brief Summary of the Consensus Discussion on the Optimal Primary Breast Cancer Treatment, Breast Care (Basel), 14, 103-110 (2019).
[35] A.G. Waks, E.P. Winer, Breast Cancer Treatment: A Review, JAMA, 321, 288-300 (2019).
[36] J.J. Kim, I.F. Tannock, Repopulation of cancer cells during therapy: an important cause of treatment failure, Nat Rev Cancer, 5, 516-525 (2005).
[37] W.L. Ng, Q. Huang, X. Liu, M. Zimmerman, F. Li, C.Y. Li, Molecular mechanisms involved in tumor repopulation after radiotherapy, Transl Cancer Res, 2, 442-448 (2013).
[38] T.M. Phillips, W.H. McBride, F. Pajonk, The response of CD24(-/low)/CD44+ breast cancer- initiating cells to radiation, J Natl Cancer Inst, 98,1777-1785 (2006).
[39] T. Tanei, K. Morimoto, K. Shimazu, S.J. Kim, Y. Tanji, T. Taguchi, Y. Tamaki, S. Noguchi, Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers, Clin Cancer Res, 15, 4234-4241 (2009).
[40] L.M. Opdenaker, K.M. Arnold, R.T. Pohlig, J.S. Padmanabhan, D.C. Flynn, J. Sims-Mourtada, Immunohistochemical analysis of aldehyde dehydrogenase isoforms and their association with estrogen-receptor status and disease progression in breast cancer, Breast Cancer (Dove Med Press), 6, 205-209 (2014).
[41] P. Marcato, C.A. Dean, D. Pan, R. Araslanova, M. Gillis, M. Joshi, L. Helyer, L. Pan, A. Leidal, S. Gujar, C.A. Giacomantonio, P.W. Lee, Aldehyde dehydrogenase activity of breast cancer stem cells is primarily due to isoform ALDH1A3 and its expression is predictive of metastasis, Stem Cells, 29, 32-45 (2011).
[42] F. Jiang, Q. Qiu, A. Khanna, N.W. Todd, J. Deepak, L. Xing, H. Wang, Z. Liu, Y. Su, S.A. Stass, R.L. Katz, Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer, Mol Cancer Res, 7, 330-338 (2009).
[43] M.P. Kim, J.B. Fleming, H. Wang, J.L. Abbruzzese, W. Choi, S. Kopetz, D.J. McConkey, D.B. Evans, G.E. Gallick, ALDH activity selectively defines an enhanced tumor-initiating cell population relative to CD133 expression in human pancreatic adenocarcinoma, PLoS One, 6, e20636 (2011).
[44] Y. Su, Q. Qiu, X. Zhang, Z. Jiang, Q. Leng, Z. Liu, S.A. Stass, F. Jiang, Aldehyde dehydrogenase 1 A1-positive cell population is enriched in tumor-initiating cells and associated with progression of bladder cancer, Cancer Epidemiol Biomarkers Prev, 19, 327-337 (2011).
[45] C.N. Landen, Jr., B. Goodman, A.A. Katre, A.D. Steg, A.M. Nick, R.L. Stone, L.D. Miller, P.V. Mejia, N.B. Jennings, D.M. Gershenson, R.C. Bast, Jr., R.L. Coleman, G. Lopez-Berestein, A.K. Sood, Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer, Mol Cancer Ther, 9, 3186-3199 (2010).
[46] P. Marcato, C.A. Dean, R.Z. Liu, K.M. Coyle, M. Bydoun, M. Wallace, D. Clements, C. Turner, E.G. Mathenge, S.A. Gujar, C.A. Giacomantonio, J.R. Mackey, R. Godbout, P.W. Lee, Aldehyde dehydrogenase 1A3 influences breast cancer progression via differential retinoic acid signaling, Mol Oncol, 9, 17-31 (2015).
[47] S.V. Johann, J.J. Gibbons, B. O'Hara, GLVR1, a receptor for gibbon ape leukemia virus, is homologous to a phosphate permease of Neurospora crassa and is expressed at high levels in the brain and thymus, J Virol, 66, 1635-1640 (1992).
[48] M.P. Kavanaugh, D.G. Miller, W. Zhang, W. Law, S.L. Kozak, D. Kabat, A.D. Miller, Cell- surface receptors for gibbon ape leukemia virus and amphotropic murine retrovirus are inducible sodium-dependent phosphate symporters, Proc Natl Acad Sci U S A, 91, 7071-7075 (1994).
[49] L. Beck, C. Leroy, S. Beck-Cormier, A. Forand, C. Salaun, N. Paris, A. Bernier, P. Urena-Torres, D. Prie, M. Ollero, L. Coulombel, G. Friedlander, The phosphate transporter PiT1 (Slc20a1) revealed as a new essential gene for mouse liver development, PLoS One, 5, e9148 (2010).
[50] K. Byskov, N. Jensen, I.B. Kongsfelt, M. Wielsoe, L.E. Pedersen, C. Haldrup, L. Pedersen, Regulation of cell proliferation and cell density by the inorganic phosphate transporter PiT1, Cell Div, 7, 7 (2012).
[51] L. Beck, C. Leroy, C. Salaun, G. Margall-Ducos, C. Desdouets, G. Friedlander, Identification of a novel function of PiT1 critical for cell proliferation and independent of its phosphate transport activity, J Biol Chem, 284, 31363-31374 (2009).
[52] J. Li, W. Dong, Z. Li, H. Wang, H. Gao, Y. Zhang, Impact of SLC20A1 on the Wnt/betacatenin signaling pathway in somatotroph adenomas, Mol Med Rep, 20, 3276-3284 (2019).
[53] K. Sato, K. Akimoto, Expression Levels of KMT2C and SLC20A1 Identified by Information- theoretical Analysis Are Powerful Prognostic Biomarkers in Estrogen Receptor-positive Breast Cancer, Clin Breast Cancer, 17, e135-e142 (2017).
[54] D.R. Rhodes, J. Yu, K. Shanker, N. Deshpande, R. Varambally, D. Ghosh, T. Barrette, A. Pandey, A.M. Chinnaiyan, ONCOMINE: a cancer microarray database and integrated data-mining platform, Neoplasia, 6, 1-6 (2004).
[55] N. Cancer Genome Atlas, Comprehensive molecular portraits of human breast tumours, Nature, 490, 61-70 (2012).
[56] C. Curtis, S.P. Shah, S.F. Chin, G. Turashvili, O.M. Rueda, M.J. Dunning, D. Speed, A.G. Lynch, S. Samarajiwa, Y. Yuan, S. Graf, G. Ha, G. Haffari, A. Bashashati, R. Russell, S. McKinney, M. Group, A. Langerod, A. Green, E. Provenzano, G. Wishart, S. Pinder, P. Watson, F. Markowetz, L. Murphy, I. Ellis, A. Purushotham, A.L. Borresen-Dale, J.D. Brenton, S. Tavare, C. Caldas, S. Aparicio, The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups, Nature, 486, 346-352 (2012).
[57] D.S. Chandrashekar, B. Bashel, S.A.H. Balasubramanya, C.J. Creighton, I. Ponce-Rodriguez, B. Chakravarthi, S. Varambally, UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses, Neoplasia, 19, 649-658 (2017).
[58] J. Kao, K. Salari, M. Bocanegra, Y.L. Choi, L. Girard, J. Gandhi, K.A. Kwei, T. Hernandez- Boussard, P. Wang, A.F. Gazdar, J.D. Minna, J.R. Pollack, Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery, PLoS One, 4, e6146 (2009).
[59] D.L. Holliday, V. Speirs, Choosing the right cell line for breast cancer research, Breast Cancer Res, 13, 215 (2011).
[60] D.H. Kim, M.A. Behlke, S.D. Rose, M.S. Chang, S. Choi, J.J. Rossi, Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy, Nat Biotechnol, 23, 222-226 (2005).
[61] C. Fougner, H. Bergholtz, J.H. Norum, T. Sorlie, Re-definition of claudin-low as a breast cancer phenotype, Nat Commun, 11, 1787 (2020).
[62] M. Kyndi, F.B. Sorensen, H. Knudsen, M. Overgaard, H.M. Nielsen, J. Overgaard, G. Danish Breast Cancer Cooperative, Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group, J Clin Oncol, 26, 1419-1426 (2008).
[63] P.L. Nguyen, A.G. Taghian, M.S. Katz, A. Niemierko, R.F. Abi Raad, W.L. Boon, J.R. Bellon, J.S. Wong, B.L. Smith, J.R. Harris, Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast- conserving therapy, J Clin Oncol, 26, 2373-2378 (2008).
[64] C. Salaun, C. Leroy, A. Rousseau, V. Boitez, L. Beck, G. Friedlander, Identification of a novel transport-independent function of PiT1/SLC20A1 in the regulation of TNF-induced apoptosis, J Biol Chem, 285, 34408-34418 (2010).
[65] S.A. Marchitti, C. Brocker, D. Stagos, V. Vasiliou, Non-P450 aldehyde oxidizing enzymes: the aldehyde dehydrogenase superfamily, Expert Opin Drug Metab Toxicol, 4, 697-720 (2008).
[66] M. Peiris-Pages, U.E. Martinez-Outschoorn, R.G. Pestell, F. Sotgia, M.P. Lisanti, Cancer stem cell metabolism, Breast Cancer Res, 18, 55 (2016).
[67] G. Vassalli, Aldehyde Dehydrogenases: Not Just Markers, but Functional Regulators of Stem Cells, Stem Cells Int, 2019, 3904645 (2019).
[68] O. Warburg, On the origin of cancer cells, Science, 123, 309-314 (1956).
[69] M.G. Vander Heiden, L.C. Cantley, C.B. Thompson, Understanding the Warburg effect: the metabolic requirements of cell proliferation, Science, 324, 1029-1033 (2009).
[70] P.J. Thornalley, The glyoxalase system: new developments towards functional characterization of a metabolic pathway fundamental to biological life, Biochemical Journal, 269, 1-11 (1990).
[71] Y. Kang, L.G. Edwards, P.J. Thornalley, Effect of methylglyoxal on human leukaemia 60 cell growth: modification of DNA, G1 growth arrest and induction of apoptosis, Leukemia research, 20, 397-405 (1996).
[72] H. Sakamoto, T. Mashima, A. Kizaki, S. Dan, Y. Hashimoto, M. Naito, T. Tsuruo, Glyoxalase I is involved in resistance of human leukemia cells to antitumor agent-induced apoptosis, Blood, The Journal of the American Society of Hematology, 95, 3214-3218 (2000).
[73] H. Sakamoto, T. Mashima, S. Sato, Y. Hashimoto, T. Yamori, T. Tsuruo, Selective activation of apoptosis program by Sp-bromobenzylglutathione cyclopentyl diester in glyoxalase I- overexpressing human lung cancer cells, Clinical cancer research, 7, 2513-2518 (2001).
[74] W.L. Cheng, M.M. Tsai, C.Y. Tsai, Y.H. Huang, C.Y. Chen, H.C. Chi, Y.H. Tseng, I.W. Chao, W.C. Lin, S.M. Wu, Glyoxalase-I is a novel prognosis factor associated with gastric cancer progression, PLoS One, 7, e34352 (2012).
[75] F. Hosoda, Y. Arai, N. Okada, H. Shimizu, M. Miyamoto, N. Kitagawa, H. Katai, H. Taniguchi, K. Yanagihara, I. Imoto, Integrated genomic and functional analyses reveal glyoxalase I as a novel metabolic oncogene in human gastric cancer, Oncogene, 34, 1196-1206 (2015).
[76] S. Ranganathan, K.D. Tew, Analysis of glyoxalase-I from normal and tumor tissue, Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, 1182, 311-316 (1993).
[77] Y. Wang, Y. Kuramitsu, T. Ueno, N. Suzuki, S. Yoshino, N. Iizuka, J. Akada, T. Kitagawa, M. Oka, K. Nakamura, Glyoxalase I (GLO1) is up-regulated in pancreatic cancerous tissues compared with related non-cancerous tissues, Anticancer research, 32, 3219-3222 (2012).
[78] S. Zhang, X. Liang, X. Zheng, H. Huang, X. Chen, K. Wu, B. Wang, S. Ma, Glo1 genetic amplification as a potential therapeutic target in hepatocellular carcinoma, International journal of clinical and experimental pathology, 7, 2079 (2014).
[79] X. Hu, X. Yang, Q. He, Q. Chen, L. Yu, Glyoxalase 1 is up-regulated in hepatocellular carcinoma and is essential for HCC cell proliferation, Biotechnology letters, 36, 257-263 (2014).
[80] M. Baunacke, L.C. Horn, S. Trettner, K.M. Engel, N.Y. Hemdan, V. Wiechmann, J.U. Stolzenburg, M. Bigl, G. Birkenmeier, Exploring glyoxalase 1 expression in prostate cancer tissues: Targeting the enzyme by ethyl pyruvate defangs some malignancy ‐ associated properties, The Prostate, 74, 48-60 (2014).
[81] T.L. Romanuik, T. Ueda, N. Le, S. Haile, T.M. Yong, T. Thomson, R.L. Vessella, M.D. Sadar, Novel biomarkers for prostate cancer including noncoding transcripts, The American journal of pathology, 175, 2264-2276 (2009).
[82] N. Kreycy, C. Gotzian, T. Fleming, C. Flechtenmacher, N. Grabe, P. Plinkert, J. Hess, K. Zaoui, Glyoxalase 1 expression is associated with an unfavorable prognosis of oropharyngeal squamous cell carcinoma, BMC cancer, 17, 382 (2017).
[83] X.Y. Zou, D. Ding, N. Zhan, X.M. Liu, C. Pan, Y.M. Xia, Glyoxalase I is differentially expressed in cutaneous neoplasms and contributes to the progression of squamous cell carcinoma, Journal of Investigative Dermatology, 135, 589-598 (2015).
[84] W.B. Bair III, C.M. Cabello, K. Uchida, A.S. Bause, G.T. Wondrak, GLO1 overexpression in human malignant melanoma, Melanoma research, 20, 85 (2010).
[85] A. Rulli, L. Carli, R. Romani, T. Baroni, E. Giovannini, G. Rosi, V. Talesa, Expression of glyoxalase I and II in normal and breast cancer tissues, Breast cancer research and treatment, 66, 67-72 (2001).
[86] B. Chiavarina, M.-J. Nokin, F. Durieux, E. Bianchi, A. Turtoi, O. Peulen, P. Peixoto, P. Irigaray, K. Uchida, D. Belpomme, P. Delvenne, V. Castronovo, A. Bellahcène, Triple negative tumors accumulate significantly less methylglyoxal specific adducts than other human breast cancer subtypes, Oncotarget, 5, 5472 (2014).
[87] M. Takeuchi, S. Kimura, J. Kuroda, E. Ashihara, M. Kawatani, H. Osada, K. Umezawa, E. Yasui, M. Imoto, T. Tsuruo, A. Yokota, R. Tanaka, R. Nagao, T. Nakahata, Y. Fujiyama, T. Maekawa, Glyoxalase-I is a novel target against Bcr-Abl+ leukemic cells acquiring stem-like characteristics in a hypoxic environment, Cell Death & Differentiation, 17, 1211-1220 (2010).
[88] Y. Nozaki, S. Tamori, M. Inada, R. Katayama, H. Nakane, O. Minamishima, Y. Onodera, M. Abe, S. Shiina, K. Tamura, D. Kodama, K. Sato, Y. Hara, R. Abe, R. Takasawa, A. Yoshimori, N. Shinomiya, S. Tanuma, K. Akimoto, Correlation between c-Met and ALDH1 contributes to the survival and tumor-sphere formation of ALDH1 positive breast cancer stem cells and predicts poor clinical outcome in breast cancer, Genes & cancer, 8, 628 (2017).
[89] R. Takasawa, K. Saeki, A. Tao, A. Yoshimori, H. Uchiro, M. Fujiwara, S. Tanuma, Delphinidin, a dietary anthocyanidin in berry fruits, inhibits human glyoxalase I, Bioorganic & medicinal chemistry, 18, 7029-7033 (2010).
[90] M.A. Fonseca-Sánchez, S. Rodríguez Cuevas, G. Mendoza-Hernández, V. Bautista-Piña, E. Arechaga Ocampo, A. Hidalgo Miranda, V. Quintanar Jurado, L.A. Marchat, E. Álvarez- Sánchez, C. Pérez Plasencia, C. López-Camarillo, Breast cancer proteomics reveals a positive correlation between glyoxalase 1 expression and high tumor grade, International journal of oncology, 41, 670-680 (2012).
[91] C.W. Elston, I.O. Ellis, Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long‐term follow‐up, Histopathology, 19, 403-410 (1991).
[92] W.L. Farrar, Cancer stem cells, Cambridge University Press2010.
[93] L.M. Opdenaker, K.M. Arnold, R.T. Pohlig, J.S. Padmanabhan, D.C. Flynn, J. Sims-Mourtada, Immunohistochemical analysis of aldehyde dehydrogenase isoforms and their association with estrogen-receptor status and disease progression in breast cancer, Breast Cancer: Targets and Therapy, 6, 205 (2014).
[94] M.H. Chen, J.J. Weng, C.T. Cheng, R.C. Wu, S.C. Huang, C.E. Wu, Y.H. Chung, C.Y. Liu, M.H. Chang, M.H. Chen, K.C. Chiang, T.S. Yeh, Y. Su, C.N. Yeh, ALDH1A3, the major aldehyde dehydrogenase isoform in human cholangiocarcinoma cells, affects prognosis and gemcitabine resistance in cholangiocarcinoma patients, Clinical Cancer Research, 22, 4225-4235 (2016).
[95] R. Takasawa, A. Tao, K. Saeki, N. Shionozaki, R. Tanaka, H. Uchiro, S. Takahashi, A. Yoshimori, S. Tanuma, Discovery of a new type inhibitor of human glyoxalase I by myricetin-based 4-point pharmacophore, Bioorganic & medicinal chemistry letters, 21, 4337-4342 (2011).
[96] R. Takasawa, N. Shimada, H. Uchiro, S. Takahashi, A. Yoshimori, S. Tanuma, TLSC702, a novel inhibitor of human glyoxalase I, induces apoptosis in tumor cells, Biological and Pharmaceutical Bulletin, 39, 869-873 (2016).
[97] N. Shimada, R. Takasawa, S. Tanuma, Interdependence of GLO I and PKM2 in the Metabolic shift to escape apoptosis in GLO I-dependent cancer cells, Archives of biochemistry and biophysics, 638, 1-7 (2018).
[98] R.S. Abdul-Maksoud, W.S. Elsayed, R.S. Elsayed, The influence of glyoxalase 1 gene polymorphism on its expression at different stages of breast cancer in Egyptian women, Genes & cancer, 8, 799 (2017).
[99] H.-T. Peng, J. Chen, T.-Y. Liu, Y.-Q. Wu, X.-H. Lin, Y.-H. Lai, Y.-F. Huang, Up-regulation of the tumor promoter Glyoxalase-1 indicates poor prognosis in breast cancer, International Journal of Clinical and Experimental Pathology, 10, 10852 (2017).
[100] D. Zhang, L.K. Tai, L.L. Wong, L.-L. Chiu, S.K. Sethi, E.S. Koay, Proteomic study reveals that proteins involved in metabolic and detoxification pathways are highly expressed in HER-2/neu- positive breast cancer, Molecular & Cellular Proteomics, 4, 1686-1696 (2005).
[101] S. Suman, T. Das, C. Damodaran, Silencing NOTCH signaling causes growth arrest in both breast cancer stem cells and breast cancer cells, British journal of cancer, 109, 2587-2596 (2013).
[102] T. Liu, B. Sun, X. Zhao, X. Zhao, T. Sun, Q. Gu, Z. Yao, X. Dong, N. Zhao, N. Liu, CD133+ cells with cancer stem cell characteristics associates with vasculogenic mimicry in triple- negative breast cancer, Oncogene, 32, 544-553 (2013).
[103] S. Yeung, J. Pan, M.H. Lee, Roles of p53, MYC and HIF-1 in regulating glycolysis—the seventh hallmark of cancer, Cellular and Molecular Life Sciences, 65, 3981 (2008).
[104] E. Charafe-Jauffret, C. Ginestier, F. Iovino, J. Wicinski, N. Cervera, P. Finetti, M.-H. Hur, M.E. Diebel, F. Monville, J. Dutcher, M. Brown, P. Viens, L. Xerri, F. Bertucci, G. Stassi, G. Dontu, D. Birnbaum, M. S Wicha, Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature, Cancer research, 69, 1302-1313 (2009).
[105] Y. Guo, Y. Zhang, X. Yang, P. Lu, X. Yan, F. Xiao, H. Zhou, C. Wen, M. Shi, J. Lu, Q. H Meng, Effects of methylglyoxal and glyoxalase I inhibition on breast cancer cells proliferation, invasion, and apoptosis through modulation of MAPKs, MMP9, and Bcl-2, Cancer biology & therapy, 17, 169-180 (2016).
[106] G. Izaguirre, A. Kikonyogo, R. Pietruszko, Methylglyoxal as substrate and inhibitor of human aldehyde dehydrogenase: comparison of kinetic properties among the three isozymes, Comparative Biochemistry and Physiology Part B: Biochemistry and Molecular Biology, 119, 747-754 (1998).
[107] J. Morgenstern, T. Fleming, D. Schumacher, V. Eckstein, M. Freichel, S. Herzig, P. Nawroth, Loss of Glyoxalase 1 Induces Compensatory Mechanism to Achieve Dicarbonyl Detoxification in Mammalian Schwann Cells, J Biol Chem, 292, 3224-3238 (2017).
[108] D. Ciavardelli, C. Rossi, D. Barcaroli, S. Volpe, A. Consalvo, M. Zucchelli, A. De Cola, E. Scavo, R. Carollo, D. D'agostino, F. Forlì, S. D'Aguanno, M. Todaro, G. Stassi, C. Di Ilio, V. De Laurenzi, A. Urbani, Breast cancer stem cells rely on fermentative glycolysis and are sensitive to 2-deoxyglucose treatment, Cell death & disease, 5, e1336-e1336 (2014).
[109] H. Hers, L. Hue, Gluconeogenesis and related aspects of glycolysis, Annual review of biochemistry, 52, 617-653 (1983).
[110] H. Feng, Y. Liu, X. Bian, F. Zhou, Y. Liu, ALDH1A3 affects colon cancer in vitro proliferation and invasion depending on CXCR4 status, British journal of cancer, 118, 224-232 (2018).
[111] Y.T. Saw, J. Yang, S.K. Ng, S. Liu, S. Singh, M. Singh, W.R. Welch, H. Tsuda, W.P. Fong, D. Thompson, V. Vasiliou, R. S Berkowitz, S. W. Ng, Characterization of aldehyde dehydrogenase isozymes in ovarian cancer tissues and sphere cultures, BMC cancer, 12, 329 (2012).
[112] Y. Nozaki, S. Tamori, M. Inada, R. Katayama, H. Nakane, O. Minamishima, Y. Onodera, M. Abe, S. Shiina, K. Tamura, D. Kodama, K. Sato, Y. Hara, R. Abe, R. Takasawa, A. Yoshimori, N. Shinomiya, S. Tanuma, K. Akimoto, Correlation between c-Met and ALDH1 contributes to the survival and tumor-sphere formation of ALDH1 positive breast cancer stem cells and predicts poor clinical outcome in breast cancer, Genes & cancer, 8, 628-639 (2017).
[113] H. Motomura, Y. Nozaki, C. Onaga, A. Ozaki, S. Tamori, T.A. Shiina, S. Kanai, C. Ohira, Y. Hara, Y. Harada, R. Takasawa, T. Hanawa, S. Tanuma, Y. Mano, T. Sato, K. Sato, K. Akimoto, High Expression of c-Met, PKCλ and ALDH1A3 Predicts a Poor Prognosis in Late-stage Breast Cancer, Anticancer Res, 40, 35-52 (2020).
[114] Y. Nozaki, H. Motomura, S. Tamori, Y. Kimura, C. Onaga, S. Kanai, Y. Ishihara, A. Ozaki, Y. Hara, Y. Harada, Y. Mano, T. Sato, K. Sato, K. Sasaki, H. Ishiguro, S. Ohno, K. Akimoto, High PKCλ expression is required for ALDH1-positive cancer stem cell function and indicates a poor clinical outcome in late-stage breast cancer patients, PLoS One, 15, e0235747 (2020).
[115] A. Marusyk, V. Almendro, K. Polyak, Intra-tumour heterogeneity: a looking glass for cancer?, Nat Rev Cancer, 12, 323-334 (2012).
[116] P.L. Bedard, A.R. Hansen, M.J. Ratain, L.L. Siu, Tumour heterogeneity in the clinic, Nature, 501, 355-364 (2013).
[117] D.A. Lawson, K. Kessenbrock, R.T. Davis, N. Pervolarakis, Z. Werb, Tumour heterogeneity and metastasis at single-cell resolution, Nat Cell Biol, 20, 1349-1360 (2018).
[118] G. Turashvili, E. Brogi, Tumor Heterogeneity in Breast Cancer, Front Med (Lausanne), 4, 227 (2017).
[119] A.G. Rivenbark, S.M. O'Connor, W.B. Coleman, Molecular and cellular heterogeneity in breast cancer: challenges for personalized medicine, Am J Pathol, 183, 1113-1124 (2013).
[120] N. McGranahan, C. Swanton, Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future, Cell, 168, 613-628 (2017).
[121] A. Kreso, C.A. O'Brien, P. van Galen, O.I. Gan, F. Notta, A.M. Brown, K. Ng, J. Ma, E. Wienholds, C. Dunant, A. Pollett, S. Gallinger, J. McPherson, C.G. Mullighan, D. Shibata, J.E. Dick, Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer, Science, 339, 543-548 (2013).
[122] N. Andor, T.A. Graham, M. Jansen, L.C. Xia, C.A. Aktipis, C. Petritsch, H.P. Ji, C.C. Maley, Pan-cancer analysis of the extent and consequences of intratumor heterogeneity, Nat Med, 22, 105-113 (2016).
[123] L. Ma, M.O. Hernandez, Y. Zhao, M. Mehta, B. Tran, M. Kelly, Z. Rae, J.M. Hernandez, J.L. Davis, S.P. Martin, D.E. Kleiner, S.M. Hewitt, K. Ylaya, B.J. Wood, T.F. Greten, X.W. Wang, Tumor Cell Biodiversity Drives Microenvironmental Reprogramming in Liver Cancer, Cancer Cell, 36, 418-430 e416 (2019).
[124] J.A. Knoblich, Mechanisms of asymmetric stem cell division, Cell, 132, 583-597 (2008).
[125] R.A. Neumuller, J.A. Knoblich, Dividing cellular asymmetry: asymmetric cell division and its implications for stem cells and cancer, Genes Dev, 23, 2675-2699 (2009).
[126] S.J. Morrison, J. Kimble, Asymmetric and symmetric stem-cell divisions in development and cancer, Nature, 441, 1068-1074 (2006).
[127] G. Driessens, B. Beck, A. Caauwe, B.D. Simons, C. Blanpain, Defining the mode of tumour growth by clonal analysis, Nature, 488, 527-530 (2012).
[128] A. Kreso, J.E. Dick, Evolution of the cancer stem cell model, Cell Stem Cell, 14, 275-291 (2014).
論文の公開元へ
